Development of thermostable vaccine adjuvants

被引:13
|
作者
Qi, Yizhi [1 ]
Fox, Christopher B. [1 ,2 ]
机构
[1] Infect Dis Res Inst IDRI, 1616 Eastlake Ave E, Seattle, WA 98102 USA
[2] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
Thermostable; vaccine adjuvant; lyophilization; spray drying; aluminum salts; emulsions; liposomes; nanoparticles; HEPATITIS-B-VACCINE; MESOPOROUS SILICA NANOPARTICLES; TRIVALENT INFLUENZA VACCINE; FREEZE-STABLE FORMULATION; DRY POWDER; DELIVERY-SYSTEM; SUBUNIT VACCINE; DOUBLE-BLIND; TUBERCULOSIS VACCINE; PROTECTIVE IMMUNITY;
D O I
10.1080/14760584.2021.1902314
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction The importance of vaccine thermostability has been discussed in the literature. Nevertheless, the challenge of developing thermostable vaccine adjuvants has sometimes not received appropriate emphasis. Adjuvants comprise an expansive range of particulate and molecular compositions, requiring innovative thermostable formulation and process development approaches. Areas covered Reports on efforts to develop thermostable adjuvant-containing vaccines have increased in recent years, and substantial progress has been made in enhancing the stability of the major classes of adjuvants. This narrative review summarizes the current status of thermostable vaccine adjuvant development and looks forward to the next potential developments in the field. Expert opinion As adjuvant-containing vaccines become more widely used, the unique challenges associated with developing thermostable adjuvant formulations merit increased attention. In particular, more focused efforts are needed to translate promising proof-of-concept technologies and formulations into clinical products.
引用
收藏
页码:497 / 517
页数:21
相关论文
共 50 条
  • [41] Trends in vaccine adjuvants
    Schijns, Virgil E. J. C.
    Lavelle, Ed C.
    EXPERT REVIEW OF VACCINES, 2011, 10 (04) : 539 - 550
  • [42] Vaccine adjuvants: A priority for vaccine research
    Harandi, Ali M.
    Medaglini, Donata
    Shattock, Robin J.
    VACCINE, 2010, 28 (12) : 2363 - 2366
  • [43] Vaccine adjuvants - Preface
    Newman, MJ
    ADVANCED DRUG DELIVERY REVIEWS, 1998, 32 (03) : 153 - 154
  • [44] Nanotechnology in adjuvants and vaccine development: what should we know?
    Assis, Bruna Rodrigues Dias
    da Silva, Caroline Dohanik
    Santiago, Marie Gabriele
    Ferreira, Lucas Antonio Miranda
    Goulart, Gisele Assis Castro
    NANOMEDICINE, 2021, 16 (29) : 2565 - 2568
  • [45] Advances in vaccine adjuvants
    Singh, M
    O'Hagan, D
    NATURE BIOTECHNOLOGY, 1999, 17 (11) : 1075 - 1081
  • [46] Liposomes as vaccine adjuvants
    Milicic, A.
    Reyes-Sandoval, A.
    Kaur, R.
    Honeycutt, J.
    Perrie, Y.
    Hill, A.
    IMMUNOLOGY, 2010, 131 : 156 - 157
  • [47] Saponins as vaccine adjuvants
    Kensil, CR
    CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 1996, 13 (1-2): : 1 - 55
  • [48] SAFETY EVALUATION OF VACCINE ADJUVANTS - NATIONAL-COOPERATIVE-VACCINE-DEVELOPMENT-MEETING-WORKING-GROUP
    GOLDENTHAL, KL
    CAVAGNARO, JA
    ALVING, CR
    VOGEL, FR
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1993, 9 : S47 - S51
  • [49] Liposomes as immunological adjuvants and delivery systems in the development of tuberculosis vaccine: A review
    Luwi, NurEllene Mat
    Ahmad, Suhana
    Azlyna, AhmadSuhaimi Nurfatihah
    Nordin, Asyikin
    Sarmiento, MariaElena
    Acosta, Armando
    Azmi, MohdNor
    Uskokovie, Vuk
    Mohamud, Rohimah
    Kadir, Ramlah
    ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2022, 15 (01) : 7 - 16
  • [50] A review of combination adjuvants for malaria vaccines: a promising approach for vaccine development
    Pirahmadi, Sakineh
    Zakeri, Sedigheh
    Djadid, Navid D.
    Mehrizi, Akram A.
    INTERNATIONAL JOURNAL FOR PARASITOLOGY, 2021, 51 (09) : 699 - 717